Apr 27, 2020
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
Apr 08, 2020
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Mar 17, 2020
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
Mar 16, 2020
Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19
Jan 16, 2019
Recent Data Collected by Spherix Global Insights Highlights Key US vs. EU Differences Between Perceptions and Adoption of Eli Lilly's Olumiant and Pfizer's Xeljanz for the Treatment of Rheumatoid Arthritis
Jan 07, 2019
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Oct 31, 2018
Sanofi Q3 2018 Performance Confirms Return to Growth
May 10, 2018
Warning to Eli Lilly's Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
Dec 13, 2017
Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day
Oct 23, 2017
US Rheumatologists Report that Use of Biologic/JAK Monotherapy in Rheumatoid Arthritis is Greatest for Pfizer's Xeljanz, Roche/Genentech's Actemra, and Sanofi/Regeneron's Recently Launched Kevzara
Jul 31, 2017
Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER
Jun 27, 2017
Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union